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The Journal of Immunology
Eomeshi NK Cells in Human Liver Are Long-Lived and Do
Not Recirculate but Can Be Replenished from the Circulation
Antonia O. Cuff,* Francis P. Robertson,† Kerstin A. Stegmann,* Laura J. Pallett,*
Mala K. Maini,* Brian R. Davidson,† and Victoria Male*
Human liver contains an Eomeshi population of NK cells that is not present in the blood. In this study, we show that these cells are
characterized by a molecular signature that mediates their retention in the liver. By examining liver transplants where donors and
recipients are HLA mismatched, we distinguish between donor liver–derived and recipient-derived leukocytes to show that
Eomeslo NK cells circulate freely whereas Eomeshi NK cells are unable to leave the liver. Furthermore, Eomeshi NK cells are
retained in the liver for up to 13 y. Therefore, Eomeshi NK cells are long-lived liver-resident cells. We go on to show that Eomeshi
NK cells can be recruited from the circulation during adult life and that circulating Eomeslo NK cells are able to upregulate Eomes
and molecules mediating liver retention under cytokine conditions similar to those in the liver. This suggests that circulating NK
cells are a precursor of their liver-resident counterparts. The Journal of Immunology, 2016, 197: 4283–4291.
N
atural killer cells are lymphocytes that were first iden-
tified by their ability to kill tumor cells without the need
for prior sensitization. The best characterized NK cells
develop in the bone marrow, circulate in the blood, and have a role
in the immune defense against viruses and cancer. However, NK
cells are also found in large numbers in nonlymphoid organs,
including the uterus and liver (1). Organ-specific NK cells differ
phenotypically from their circulating counterparts and are also
likely to have specialist physiological functions relevant to their
home organs (2). For example, uterine NK cells mediate placental
implantation during pregnancy (3, 4).
Recently, NK cells in the liver have been a focus of intense
research interest. In mice, splenic NK cells almost uniformly
express the T-box transcription factor Eomes, but in the liver, a
distinct population of Eomes2 NK cells is also present (5). These
murine Eomes2 NK cells have an immature phenotype and were
originally thought to be precursors to Eomes+ circulating NK cells
(5). More recently, it has been proposed that Eomes2 liver NK
cells form a separate lineage from Eomes+ circulating NK cells
(2, 6). Suggestively, the transcription factors required for the de-
velopment of the two NK cell subsets differ, with circulating NK
cells requiring Eomes (5) and E4bp4 (2, 7, 8), whereas liver NK
cells develop independently of these, but instead require T-bet (2,
5, 6). Furthermore, sorted Eomes-GFP2 liver NK cells are not able
to differentiate into Eomes+ NK cells (6). Parabiosis experiments
show that T-bet–dependent liver NK cells, defined in these studies
as DX52CD49a+, do not leave the liver, providing definitive ev-
idence that these NK cells are liver resident (2, 9).
There have been three recent reports of NK cell subsets enriched
in human liver, compared with blood, defined either as CD49a+
(10), CD56bright (11), or CXCR6+ (12). The enrichment of these
subsets in liver, and their expression of CD69, is suggestive of
residency, but the difficulties of working with human subjects
mean that definitive experiments to address whether these NK
cells are liver resident have not yet been performed (13).
We previously postulated that human liver, similar to that of the
mouse, might contain a liver-specific NK cell population defined by
its lack of Eomes expression. Human liver does contain an NK cell
population that is not present in blood but, in contrast to the liver-
specific population in the mouse, it is Eomeshi (12). In this study,
we demonstrate that these cells express a signature of molecules
that mediate their retention in the liver. Working with HLA-
mismatched human liver transplants, we show that Eomeshi NK
cells are not able to exit the liver and are long-lived, capable of
surviving in the liver for up to 13 y. This indicates that these are
genuine liver-resident cells. Eomeshi NK cells can be replenished
from the circulation during adult life, and cytokines found at high
concentrations in the liver promote the upregulation of Eomes.
This suggests that, in humans, Eomeslo circulating NK cells may
be recruited to the liver where they upregulate Eomes becoming
long-lived liver-resident cells.
Materials and Methods
Samples
Perfusion fluid was obtained from 16 healthy livers used for transplantation
and 11 healthy livers that were unsuitable for transplantation due to vascular
abnormalities, long warm ischemic time, or because of primary tumors
found in other organs. Sixteen of the donors were male and 11 female with
age range of 15–74 y (median, 42 y). Biopsies were taken from the
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explanted livers of five patients receiving their second liver transplant.
Ethical approval for use of blood, perfusates, and explanted liver biopsies
was obtained through the Royal Free Hospital Biobank (National Health
Service Research Ethics Committee approval no. 11/WA/0077, study no.
9455). Pre- and postimplant biopsies were collected as part of the RIPCOLT
trial (National Health Service Research Ethics Committee approval no. 11/
H0720/4, trial number 8191).
Leukocytes from perfusion fluid were concentrated by centrifugation
(750 3 g, 15 min, 20˚C). The concentrated cells were layered onto Ficoll
(GE Healthcare, Amersham, U.K.), centrifuged (400 3 g, 20 min, 20˚C,
light braking), and the interface was taken and washed twice with PBS
(750 3 g, 15 min, 20˚C). Tissue from explanted livers were finely minced
using scalpels, passed through a 70-mm strainer, and the collected cells
were layered onto Ficoll, centrifuged (400 3 g, 20 min, 20˚C, light
braking), and the interface was taken and washed twice with PBS (750 3 g,
15 min, 20˚C). Trucut biopsies were pushed through a 40-mm strainer and
the cell suspension was used without further purification.
Flow cytometry
The following Abs were used: from eBioscience (San Diego, CA): CD3-
allophycocyanin eFluor 780 (clone SK7), CD16-FITC (eBioCB16), CD19-
allophycocyanin eFluor 780 (HIB19), CD45-PE (HI30), CD94-FITC
(DX22), Eomes-PE eFluor 610 (WD1928), granzyme K–PerCP eFluor
710 (G3H69), HLA-A3-FITC (GAP.A3), IFN-g–Alexa Fluor 488 (4S.B3),
S1PR1–eFluor 660 (SW4GYPP), T-bet–PE-Cy7 (4B10), and TNF-a–
allophycocyanin (Mab11); from BioLegend (London, U.K.): CCR5-
allophycocyanin (J418F1), CD49a-FITC (TS2/7), CD69-allophycocyanin
(FN50), CD103-FITC (Ber-ACT8), CX3CR1-FITC (2A9-1), CXCR6-PerCP
Cy5.5 (K041E5), CXCR6-allophycocyanin (K041E5), GM-CSF–PE (BDV-
21C11), granzyme B–FITC (GB11), HLA-A2–FITC (BB7.2), KIR2DL1/S1/
S3/S5-allophycocyanin (HP-MA4), KIR2DL2/L3-allophycocyanin (DX27),
KIR3DL1-allophycocyanin (DX9), and perforin-allophycocyanin (dG9); and
from BD Biosciences (Oxford, U.K.): CD56-BV510 (NCAM16.2) and LIF-
PE (1F10). Dead cells were excluded using fixable viability dye eFluor 450
(eBioscience). Intracellular staining was carried out using Human FoxP3
Buffer (BD Biosciences) according to the manufacturer’s instructions. Data
were acquired on an LSRFortessa II (BD Biosciences) and analyzed using
FlowJo (Tree Star, Ashland, OR). Cells were sorted on a FACSAria (BD
Biosciences). Eomeslo NK cells were isolated by sorting on live cells (pro-
pidium iodide2, Tonbo Biosciences, San Diego, CA), singlets, scatter, and
CD32CD56+CXCR62CD16+. Eomeshi NK cells were isolated by sorting on
live cells, singlets, scatter, and CD32CD56+CXCR6+.
RNA sequencing
Total RNA was extracted from sorted cells using an RNeasy Micro kit
(Qiagen, Manchester, U.K.), and cDNA was amplified using a SMART-Seq
ultra-low input RNA kit for sequencing (Takara Bio Europe/Clontech, Saint-
Germain-en-Laye, France). Amplified cDNA (200 pg) was used as input for
library preparation using a Nextera XT DNA library preparation kit (Illumina,
Essex, U.K.) with 12 cycles of PCR. Samples were sequenced on a NextSeq
500 (Illumina). Alignments were performed using TopHat, and regularized
log-transformed normalization was performed using DESeq2 (BaseSpace;
Illumina). Expression of each genewas compared using a paired t test. Further
analysis was undertaken by Ingenuity Pathway Analysis (Qiagen) with a fold
change cutoff of 2 and a significance cutoff of 0.01.
Functional assays
Sorted cells were cultured with K562 for 4 h at a 1:1 ratio in 50 ml of RPMI
1640 medium supplemented with 10% FCS, 25 mM HEPES, 1 mM so-
dium pyruvate, 50 mM 2-ME, MEM nonessential amino acids, penicillin,
and streptomycin (all Life Technologies brand; Thermo Fisher Scientific,
Hudson, NH). Cells were harvested and stained with Annexin VFITC (BD
Biosciences) and propidium iodide.
Freshly isolated perfusate cells (106) were stimulated with PMA (25 ng/ml;
Sigma-Aldrich, Hammerhill, U.K.) and ionomycin (1 mg/ml; Sigma-Aldrich)
for 4 h with brefeldin A (10 mg/ml; Sigma-Aldrich), monensin (2 mM; Sigma-
Aldrich), and 5 ng/ml PerCP–eFluor 710-conjugated anti-human CD107a
(clone eBioH4A3; eBioscience). Intracellular staining for cytokines was
performed at the end of the assay.
In vitro differentiation assays
Cells were plated at 2.53 104/ml in RPMI 1640 medium, supplemented as
before, and with 5 ng/ml recombinant human IL-7 (PeproTech, Rocky Hill,
NJ). Recombinant human IL-15 (20 ng/ml), IL-12 (50 ng/ml), or TGF-b
(5 ng/ml) (all PeproTech) was added. Cells were cultured for 7 d with a
half medium change at days 2 and 5.
NKL transduction
Lentivirus was produced by transfecting 293T cells with pCSGW-IRES-
dsRed (vector) or pCSGW-Eomes-IRES-dsRed and the packaging plas-
mids psPAX2 and pMD2.G (deposited at Addgene as plasmids p12259 and
p12260, respectively, by D. Trono, E´cole Polytechnique Fe´de´rale de
Lausanne, Lausanne, Switzerland). NKL cells were transduced by spin-
fection at 700 3 g and 20˚C for 45 min with 10 mg/ml Polybrene (Sigma-
Aldrich) and cultured for a further 72 h before harvesting and examination.
Results
Eomeshi NK cells are present in human liver but not in blood
and have a distinct phenotype
Prior to transplantation, donor livers are perfusedwith coldUniversity
of Wisconsin fluid. The perfusion fluid (perfusate) contains large
numbers of leukocytes with a composition that mirrors that found in
biopsies (11, 12, 14). Examining perfusates from 11 transplanted
livers, we confirmed our previous findings that both Eomeslo and
Eomeshi NK cells were present in human liver, whereas circulating
NK cells were uniformly Eomeslo (Fig. 1A–C) (12).
We postulated that these Eomeshi liver-specific NK cells might
have a specialist physiological function. To take an unbiased approach
to this question, we sorted Eomeslo and Eomeshi NK cells from five
perfusates and performed RNA sequencing (RNAseq) analysis (the
RNAseq data and differentially expressed gene list were deposited at
National Center for Biotechnology Information Gene Expression
Omnibus under accession no. GSE87392; https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE87392). Ingenuity Pathway Analysis
(Fig. 1D) identified the two most significantly enriched canonical
pathways as NK cell signaling (p = 1.12 3 1026) and Th cell sig-
naling (p = 1.10 3 1025), although neither of these was identified as
being more highly activated in either NK cell subset. Among the 15
most significantly enriched canonical pathways, leukocyte extrava-
sation signaling was the most highly activated in Eomeshi NK cells
(p = 1.743 1023; z-score = 1.528), whereas sphingosine-1-phosphate
signaling was the most highly activated in Eomeslo NK cells (p = 1.173
1023; z-score = 21.667). Other canonical pathways in the top
15 were mostly those whose component genes overlap with these
pathways, for example ILK signaling (large overlap with leukocyte
extravasation signaling) and ceramide signaling (large overlap with
sphingosine-1-phosphate signaling). The top upstream regulator was
TGF-b1 (p = 4.01 3 10215).
We next examined protein expression of some genes identified
as differing at the transcript level (Fig. 1E). Eomeshi NK cells
expressed higher levels of CXCR6 and CCR5 than did Eomeslo
NK cells, but lower levels of CX3CR1, in agreement with previ-
ous observations on bulk liver NK cells compared with blood (11)
and similar to NK cells enriched in lymphoid organs (15). S1PR1,
which mediates migration of immune cells from tissues into the
circulation (16), was expressed at lower levels on Eomeshi NK
cells, whereas CD69, which negatively regulates S1PR1, was
expressed at higher levels, similar to findings in other subsets of
NK cells proposed to be resident in the liver or lymphoid organs
(10, 11, 15). ITGA1, which encodes the key marker of liver res-
idency in mice, integrin a1 (or CD49a) (2, 9), and has been pro-
posed to define liver-resident NK cells in humans (10) was highly
overexpressed in Eomeshi NK cells at the transcript level, but we
were unable to detect any difference in protein expression. ITGAE
encodes integrin aE, or CD103, a marker of residence in CD8
+
memory T cells (17), and it was also overexpressed by Eomeshi
NK cells at the transcript level, but again we were unable to detect
a difference at the protein level.
In agreement with the RNAseq data, Eomeshi NK cells express
killer cell Ig-related receptors at a far lower frequency than do
Eomeslo NK cells, but CD94 (coreceptor to NKG2A, or KLRC2)
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is expressed at a higher frequency. Eomeshi NK cells also express
lower levels of perforin and granzyme B but higher levels of
granzyme K. The decreased expression of proteins associated with
cytotoxicity on Eomeshi NK cells might suggest that they are less
cytotoxic than their Eomeslo counterparts. Indeed, Eomeshi NK
cells were somewhat less able to kill K562 target cells than were
FIGURE 1. Eomeshi NK cells are present in human liver and have a distinct phenotype. (A) PBLs were isolated from healthy volunteers and NK cells
identified by gating on live cells, scatter, CD32, and CD56+. NK cells were examined for their expression of Eomes and T-bet. (B) Leukocytes were isolated
from the perfusion fluid of healthy human livers destined for transplantation and stained as in (A). (C) Summary data showing Eomeshi NK cells as a
percentage of total NK cells across 11 samples. Significance was determined using a Mann–Whitney U test. (D) RNASeq data from Eomeslo and Eomeshi
NK cells sorted from the perfusion fluid from n = 5 healthy livers. Differentially expressed genes were identified using paired t tests. The top 10 most
differentially expressed genes and the top most significantly enriched canonical pathways are shown. (E) Flow cytometry for key proteins expected to differ
between Eomeslo (blue dashed line) and Eomeshi (red solid line) liver NK cells. Histograms are representative of n = 4 independent samples. (F) Overlap
between top upregulated genes in Eomeslo and Eomeshi liver NK cells, compared with tonsil NK cells and ILC1 (23).
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Eomeslo NK cells, although both did have some cytotoxic capacity
(Supplemental Fig. 1A). Perhaps surprisingly, given their lesser
ability to kill target cells, it was the Eomeshi NK cells that had the
greater propensity for degranulation (Supplemental Fig. 1B). We
assessed IFN-g, TNF-a, and GM-CSF production (Supplemental
Fig. 1C–E), because these have been shown to differ between
Eomes2 and Eomes+ NK cells in mice (2, 5, 6, 9, 18). Among
these, the only cytokine to differ between the subsets was TNF-a,
which was produced at somewhat lower levels by Eomeshi NK
cells. Finally, we assessed the ability of the cells to produce LIF,
because this was one of the most upregulated genes in Eomeshi
NK cells by RNAseq, and IL-22, because IL-23R was also over-
expressed in Eomeshi NK cells. However, under the conditions
examined, both subsets made very little of either of these cyto-
kines and there was no significant difference between them
(Supplemental Fig. 1F, 1G). We undertook all these experiments
under a variety of conditions, including coculture with K562,
culture with IL-12 alone, culture with IL-12 and IL-18, and (for
IL-22 production) 4-h culture with IL-1b and IL-23 and overnight
culture with IL-1b and IL-23, followed by restimulation with
PMA and ionomycin. In all cases the results were similar to 4-h
culture with PMA and ionomycin (Supplemental Fig. 1B–G).
Neither liver NK cell subset resembles innate lymphoid cell
types 1 or 3
In light of suggestions that liver-resident Eomes2 NK cells in mice
represent innate lymphoid cell (ILC)1, whereas the Eomes+ pop-
ulation represents conventional NK cells (19), we sought to assess
whether either liver NK cell subset found in humans closely
resembled ILC1. Two ILC1 populations have been defined in
human lymph nodes: a lineage2 (CD562)CD127+CRTH2+c-Kit2
NKp442 population (20) and a CD56+NKp44+CD103+ population
(21). Neither liver NK cell population is phenotypically identical
to these, because they are both CD56+ and CD1032 (Fig. 1B, 1E).
However, ILC1 notoriously varies in its phenotype between organs
(22), so this does not rule out that one of these subsets might
represent ILC1. Therefore, we used data on the whole tran-
scriptomes of ILC1 and NK cells sorted from human lymph nodes
(23) to generate a list of differentially expressed genes using the R
package SCDE (24). Comparing this to the genes differentially
expressed between Eomeslo and Eomeshi liver NK cells revealed
that each NK subset shared roughly the same proportion of genes
with both conventional NK cells and ILC1 isolated from the
tonsils (Fig. 1F). We also considered the possibility that one of the
liver NK cell subsets might represent a CD56+ ILC3 population.
However, neither NK subset produced significant IL-22 with any
of the stimulation regimes we tried (Supplemental Fig. 1G).
Therefore, we conclude that both the Eomeslo and the Eomeshi
CD32CD56+ subsets present in the liver are likely to represent
NK cells, and not helper ILCs.
Eomeshi NK cells do not exit the liver and are long-lived in
the liver
The findings that Eomeshi NK cells were present in liver but not
blood, and that the most altered pathways in Eomeshi NK cells are
associated with blood exit and tissue retention, suggested that
Eomeshi NK cells might represent a liver-resident population. To
investigate this possibility, we designed experiments to assess
whether Eomeshi NK cells are capable of leaving the liver and
whether they are long-lived in the liver.
We identified seven liver transplants in which the donor and re-
cipient were mismatched for either HLA-A2 or HLA-A3. In these
transplants, we could distinguish between donor liver–derived and
recipient leukocytes by staining with Abs specific for the mismatched
HLA. We examined the composition of leukocytes in donor liver
perfusate before the transplant and in recipient blood 24–48 h after
the transplant (clinical details are given in Supplemental Table I). As
expected, before transplantation both Eomeslo and Eomeshi NK cells
were present in donor livers (Fig. 2A, 2C), and only Eomeslo NK
cells were present in recipient blood. After transplant, we were able
to identify cells in the recipient’s blood that had recently exited the
donor liver. NK cells were among these but were uniformly Eomeslo
(Fig. 2B, 2C), indicating that only Eomeslo NK cells are able to leave
the liver. We also examined three paired pretransplant and 3 h
posttransplant liver biopsies (Fig. 2D–F). The proportion of donor
liver–derived Eomeslo NK cells decreased after transplant, in support
of the idea that Eomeslo NK cells are able to leave the liver. Taken
together, these findings indicate that Eomeslo NK cells recirculate
whereas Eomeshi NK cells do not, consistent with the hypothesis that
Eomeshi NK cells are liver resident.
Another hallmark of residence is longevity. To determine whether
Eomeshi NK cells are long-lived in the liver, we identified five
patients who had previously received a liver transplant mismatched
for either HLA-A2 or HLA-A3 and were now receiving their sec-
ond transplant (clinical details are given in Supplemental Table I).
We isolated leukocytes from the explanted first transplant and
distinguished between donor liver–derived and recipient-derived
cells to determine which leukocytes were able to survive in the
liver without replenishment from the circulation. One important
caveat is that most of the patients receiving their second transplant
were already undergoing immunosuppressive therapy following
their first transplant, or they were suffering from immune-mediated
complications, or both. However, we did find that the proportions of
T cells, NK cells, and Eomeslo and Eomeshi cells as a proportion of
total NK cells were not significantly different between healthy
livers, disease controls receiving their first transplant, and our co-
hort of five retransplant patients, suggesting that our findings are
likely to be broadly representative of the situation in healthy liver
and other liver diseases (Supplemental Fig. 2).
Eomeslo NK cells retained in the liver were present in the three
biopsies taken immediately after transplant (Fig. 2E, 2F) and in livers
explanted 8 d and even 3 y posttransplant (Fig. 3A, 3B), but they were
barely detectable in livers collected $6 y posttransplant (Fig. 3C–E).
This is consistent with Eomeslo NK cells continually leaving the liver
and being replaced from the circulation. In contrast, liver-derived
Eomeshi NK cells were present in all livers examined (Fig. 3A–E),
persisting in small numbers even in the liver collected 13 y post-
transplant. This suggests that the Eomeshi NK cell population is in-
deed long-lived and supports the view that it is liver resident.
Eomeshi liver NK cells can be recruited from the circulation
Our examination of recipient-derived cells isolated from post-
transplant biopsies showed that Eomeslo NK cells are rapidly
recruited from the circulation (Fig. 2E). At this early time, no
recipient-derived Eomeshi NK cells are present. This is unsur-
prising, because Eomeshi NK cells do not circulate. However,
when we examined the recipient-derived cells present in explanted
livers (Fig. 3) we found Eomeslo circulating NK cells, as expected,
but also Eomeshi NK cells, present even as early as 8 d post-
transplant (Fig. 3A). This suggested that some precursor of the
Eomeshi NK cells could be recruited to the liver from the circu-
lation. Given that circulating Eomeslo NK cells are rapidly
recruited to the liver (Fig. 2E), we investigated the possibility that
these could be precursors of Eomeshi liver-resident NK cells.
Eomeslo NK cells can upregulate Eomes
We first sought to determine whether Eomeslo and Eomeshi NK
cells in the liver form separate lineages, as is thought to be the
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case in mice (6). We therefore sorted the two NK cell populations
and cultured them for 7 d to assess their ability to cross-
differentiate. We included IL-15 in all culture conditions be-
cause it is required for NK cell development and survival (25, 26).
TGF-b was included in one condition because it was identified as
a top upstream regulator in our RNAseq experiment, it is highly
expressed in the liver (27), and it promotes residence in CD8+
memory T cells (17, 28). This condition might be expected to
move Eomes2 NK cells toward Eomes expression. IL-12 was
included in another condition because it promotes T-bet expres-
sion (29–31) and T-bet negatively regulates Eomes (32, 33), so
this condition might be expected to move Eomeshi (T-betlo) NK
cells toward an Eomeslo (T-bethi) phenotype.
Under all these conditions, Eomeslo liver NK cells upregulated
Eomes and downregulated T-bet (Fig. 4A, 4D). We were less suc-
cessful at causing Eomeshi NK cells to downregulate Eomes, even
on culture with high concentrations of IL-12 (Fig. 4B, 4E), although
under these conditions they did somewhat increase their expression
of T-bet. In vitro–differentiated NK cells did not alter their ex-
pression of CXCR6 (Fig. 5A), confirming that the Eomeslo NK cells
increased Eomes expression, rather than the observations resulting
from outgrowth of contaminating Eomeshi (CXCR6+) cells.
Having shown that Eomeslo NK cells in the liver can become
Eomeshi, we sought to determine whether the same is also true of
Eomeslo peripheral blood NK cells. Similar to Eomeslo liver NK
cells, sorted CD32CD56+ blood NK cells upregulated Eomes in
culture (Fig. 4C, 4F), supporting the hypothesis that circulating
NK cells could, under the influence of cytokines that are highly
expressed in the liver, acquire Eomes expression.
Eomes upregulation is associated with increased expression of
mediators of tissue retention
If circulating NK cells are recruited to the liver, upregulating
Eomes and concomitantly becoming liver resident, it seems likely
that Eomes is causing altered expression of chemokine receptors,
integrins, and S1PR1, which results in the cells being retained in the
liver. To further investigate this, we examined cell surface ex-
pression of CXCR6, CCR5, CX3CR1, CD49a, CD103, and S1PR1
in freshly isolated Eomeslo peripheral blood NK cells and pe-
ripheral blood NK cells that had been cultured for 7 d in IL-15 and
FIGURE 2. Eomeslo NK cells exit the liver but Eomeshi NK cells do not. (A and B) Example of staining from a single transplant in which an HLA-A3–
negative liver (A) was transplanted into an HLA-A3–positive recipient. Twenty-four hours after transplant, PBLs were isolated from the recipient’s blood and
circulating liver-derived cells were distinguished from recipient-derived cells on the basis of HLA-A3 staining (B). NK cells were examined for their expression
of Eomes and T-bet. (C) Summary data from n = 7 transplants mismatched at either HLA-A2 or HLA-A3. Significance was determined using a paired t test. (D
and E) Example staining from a single transplant in which an HLA-A2–positive liver (D) was transplanted into an HLA-A2–negative recipient. Three hours
posttransplant, a second biopsy was taken from the liver and liver-derived cells were distinguished from recipient-derived cells on the basis of HLA-A2
staining (E). (F) Summary data from n = 3 transplants, all mismatched at HLA-A2. The gates used to produce the summary data (C and F) are highlighted.
The Journal of Immunology 4287
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TGF-b to promote the upregulation of Eomes (Fig. 5A). We found
no change in the expression of CXCR6 during culture, but we did
find that CCR5 expression increased whereas CX3CR1 and
S1PR1 decreased, consistent with Eomeshi liver NK cells isolated
ex vivo. We also found that the expression of CD49a and CD103
increased in in vitro–differentiated Eomeshi NK cells, consistent
with the increased expression of ITGA1 (CD49a) and ITGAE
(CD103) mRNA in Eomeshi NK cells isolated ex vivo.
These observations suggested that Eomes might directly alter the
expression of genes that act to retain NK cells in the liver. However,
it is also possible that the alterations we observed were caused by
other aspects of the culture conditions, rather than being Eomes
mediated. To more precisely define which genes were altered
specifically as a result of Eomes expression, we lentivirally
transduced NKL cells with either empty vector or Eomes and
examined transduced cells (Fig. 5B). NKL cells are derived from a
human NK cell leukemia (34). We used this cell line because it is
more easily transduced than primary peripheral blood NK cells
and yet is identical to them with respect to expression of Eomes,
CD49a, CD103, and S1PR1. Unlike peripheral blood NK cells
(but similar to other NK cell lines), NKL cells express inter-
mediate levels of CCR5, CXCR6, and CX3CR1, so we did not
examine alterations in these chemokine receptors. Eomes-transduced
NKL cells expressed higher levels of CD49a and CD103 than did
control-transduced cells (Fig. 5B), suggesting that the increase in
the expression of these integrins in in vitro–differentiated Eomeshi
NK cells may be a direct result of Eomes action. In contrast, S1PR1
expression did not differ, indicating that decreased S1PR1 expres-
sion in both ex vivo–isolated and in vitro–differentiated Eomeshi
NK cells may not be a direct result of the action of Eomes.
Discussion
Recent years have seen an explosion in interest in liver-specific NK
cells and particularly in the idea that there may be a liver-resident
subset of NK cells. In mice, these liver-resident NK cells have been
characterized in detail. They are dependent on T-bet but inde-
pendent of Eomes and, using parabiosis experiments, have been
definitively shown not to recirculate (2, 5, 6, 9). We took a
comparable approach to identify liver-resident NK cells in hu-
mans. Similar to mouse liver, human liver contains both Eomeslo
and Eomeshi NK cell subsets but, in contrast to the mouse, the
Eomeslo NK subset is present in both blood and liver whereas the
Eomeshi subset is restricted to the liver. The transcription factors
regulating circulating versus liver-resident NK cells, therefore,
FIGURE 3. Eomeshi NK cells are
long-lived in the liver, but they can be
recruited from the circulation during
adult life. (A) An HLA-A2–positive
liver was transplanted into an HLA-
A2–negative recipient and removed 8 d
later. Liver leukocytes were isolated
from a biopsy and liver-derived cells
were distinguished from recipient-
derived cells on the basis of HLA-A2
staining. Liver- and recipient-derived
NK cells present in the liver were ex-
amined for their expression of Eomes
and T-bet. (B) An HLA-A2–positive
liver was transplanted into an HLA-
A2–negative recipient and removed
3 y later. (C) An HLA-A2–positive
liver was transplanted into an HLA-
A2–negative recipient and removed
6 y later. (D) An HLA-A3–positive
liver was transplanted into an HLA-
A3–negative recipient and removed
6 y later. (E) An HLA-A2–positive
liver was transplanted into an HLA-
A2–negative recipient and removed
13 y later.
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seem to be reversed in humans compared with mice. This is
consistent with a report of an infant with a silencing mutation in
Eomes, who presented with a normal distribution of circulating
NK cells, suggesting that Eomes is not required for their devel-
opment in humans (35). That these two T-box transcription factors
could have switched roles over the course of evolution should
perhaps not be surprising in the light of their highly homologous
nature and often redundant roles (36, 37).
By RNAseq, the most altered canonical pathways between the
two liver NK cell subsets were associated with blood exit and tissue
retention, and this suggests that the main difference between
Eomeslo and Eomeshi NK cells is that the Eomeshi population is
liver resident. An earlier study showed that some NK cells can be
retained in the liver for up to 2 y (38). We have extended this work
by showing that some NK cells are retained for up to 13 y and that
these long-term resident NK cells are the Eomeshi population.
This demonstration that Eomeshi NK cells are unable to re-enter
the circulation and are long-lived in the liver provides, to our
knowledge for the first time, evidence of a bona fide liver-resident
NK cell population in humans. To our knowledge, this is also the
first such demonstration of a resident NK cell population in any
human tissue.
Examination of recipient-derived cells from transplanted livers
removed between 8 d and 13 y posttransplant further revealed that
Eomeshi liver-resident NK cells can be recruited from the circu-
lation during adult life. Eomeslo NK cells can become Eomeshi
when exposed to IL-15 and TGF-b, which are highly expressed in
the liver (27, 39). This suggests that one source of Eomeshi liver
NK cells is circulating Eomeslo NK cells, although these experi-
ments do not rule out the possibility that Eomeshi liver NK cells
also derive, at least in part, from circulating CD34+ hematopoietic
stem cells or NK progenitor cells (38, 40). There have been two
recent reports of a small population of CXCR6+ NK cells in the blood,
although these, unlike CXCR6+ NK cells in the liver, are Eomeslo
(12, 15). One possibility, then, is that circulating CXCR6+Eomeslo
NK cells are recruited to the liver by CXCL16, which is highly
expressed by liver sinusoidal endothelial cells (11, 41) and there
upregulate Eomes.
Our finding that Eomeslo NK cells could give rise to Eomeshi
NK cells was unexpected in the light of work in mice, showing
that liver-resident and circulating NK cells form separate lineages
(6). It is, of course, likely that human and mouse NK cells differ in
this respect, as they do in so many others. However, note that
sorted circulating-type NK cells in mice can give rise to a small
number of liver-type NK cells during 2 wk in vivo, so there may
be some degree of flexibility between the lineages, even in mice
(6). Furthermore, when bone marrow is transferred to a lethally
irradiated mouse, a small proportion of donor-derived liver-
resident NK cells are present 3 mo later (9), and when ILC pro-
genitors are transferred to a Rag/gc double knockout host,
donor-derived liver-specific NK cells are present after 3–6 wk
(42). Therefore in mice, as we show in humans, there may also be
some replacement of liver-resident NK cells from the circulation
during adult life.
FIGURE 4. Eomeslo NK cells can become Eomeshi.
(A and B) NK cells were sorted from perfusion fluid
[(A), Eomeslo; (B), Eomeshi)] and cultured for 7 d in the
indicated conditions. At the end of the culture period,
the cells were examined for their expression of Eomes
and T-bet. (C) Sorted blood NK cells were cultured as
above. (D–F) Summary data showing the percentage of
Eomeshi NK cells in n = 4 independent experiments,
starting with Eomeslo liver NK cells (D), Eomeshi liver
NK cells (E), or Eomeslo peripheral blood NK cells (F).
Groups that are significantly different (p , 0.05 by
one-way ANOVA) are indicated by different letters.
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In vitro–differentiated Eomeshi NK cells mirrored their ex vivo–
isolated counterparts in their expression of CCR5, CX3CR1, and
S1PR1. However, they did not express increased CXCR6. This
is consistent with the proposition that CXCR6 causes recruitment
to the liver where the cytokine environment promotes Eomes
upregulation, as opposed to the alternative that Eomes causes
CXCR6 expression. We also found increased expression of CD49a
and CD103, strikingly similar to recent findings that TGF-b
causes the upregulation of these integrins in circulating NK cells
recruited to the salivary gland in the mouse (43). This is also in
line with mRNA expression in freshly isolated Eomeshi NK cells,
although we did not detect a difference in protein expression ex
vivo. It is possible that ex vivo–isolated Eomeshi NK cells do
express these proteins but at subdetectable levels, or that they
express mRNA and are poised to produce protein but only do
so under particular conditions. Transduction of NKL cells with
Eomes also caused an increase in the expression of these integrins
but did not alter expression of S1PR1. This could indicate that
IL-15 and TGF-b alter S1PR1 via a parallel, Eomes-independent
pathway, but could also potentially be a result of differences between
the NKL cell line and primary NK cells. Nonetheless, it seems clear
that IL-15 and TGF-b can cause peripheral blood NK cells to up-
regulate Eomes and concomitantly alter their expression of chemo-
kine receptors, integrins, and S1PR1 in such a way as to promote
retention in the liver, and that the alteration in integrin expression, at
least, is likely to be a direct consequence of Eomes expression.
We therefore propose that CXCR6+Eomeslo circulating NK cells
are recruited to the liver by CXCL16 (12, 15, 41), where they are
exposed to high concentrations of IL-15 and TGF-b (27, 39)
causing the upregulation of Eomes. This in turn alters cell surface
expression of chemokine receptors, integrins, and S1PR1 such that
the Eomeshi NK cells become unable to leave the liver and turn
into long-lived resident cells. The precise function of these cells
remains to be defined but, as has been suggested in the mouse,
their residency may point to tissue-specific homeostatic functions
(2). There is also some evidence that liver-resident NK cells in the
mouse are memory cells (9, 44). The longevity of Eomeshi NK
cells in human liver could point to these cells also having memory,
although this is an idea that will be challenging to test in humans.
The distinction between circulating and liver-resident NK cells
in humans may also prove clinically relevant. Recently, evidence
has emerged that the main drivers of ischemia-reperfusion injury in
mouse kidney are resident NK cells (45). If the same proves to be
true of human liver, this could suggest that targeting these cells in
the donor liver prior to implantation may present a novel target to
ameliorate ischemia-reperfusion injury in the setting of liver
transplantation. Finally, the finding that a large proportion of the
NK cells present in organs are likely to be resident suggests that
we should reconsider the tendency to assume that observations
made on NK cells circulating in the blood necessarily signify
anything about their organ-resident counterparts (46, 47).
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